Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

Resident Endothelial Cells and Endothelial
Progenitor Cells Restore Endothelial Barrier
Function After Inflammatory Lung Injury
S. Z. Mao
Northwell Health

X. B. Ye
Northwell Health

G. Liu
Northwell Health

D. M. Song
Northwell Health

S. F. Liu
Zucker School of Medicine at Hofstra/Northwell

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Critical Care Commons, and the Pulmonology Commons
Recommended Citation
Mao S, Ye X, Liu G, Song D, Liu SF. Resident Endothelial Cells and Endothelial Progenitor Cells Restore Endothelial Barrier Function
After Inflammatory Lung Injury. . 2015 Jan 01; 35(7):Article 2037 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/2037. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

HHS Public Access
Author manuscript
Author Manuscript

Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2016 July 01.
Published in final edited form as:
Arterioscler Thromb Vasc Biol. 2015 July ; 35(7): 1635–1644. doi:10.1161/ATVBAHA.115.305519.

Resident Endothelial Cells and Endothelial Progenitor Cells
Restore Endothelial Barrier Function Following Inflammatory
Lung Injury
Sun-zhong Mao#1,2, Xiaobing Ye#1, Gang Liu1, Dongmei Song1, and Shu Fang Liu1,2
1Centers

Author Manuscript

for Heart and Lung Research, and Pulmonary and Critical Care Medicine, the Feinstein
Institute for Medical Research, Manhasset, NY 11030, U.S.A.

2Institute

#

of Hypoxia Medicine, Wenzhou Medical University, Wenzhou 325035, China.

These authors contributed equally to this work.

Abstract
Objective—Disruption of endothelial barrier integrity is a characteristic of many inflammatory
conditions. However, the origin and function of endothelial cells (ECs) restoring endothelial
barrier function remain unknown. This study defined the roles of resident ECs (RECs) and bone
marrow-derived endothelial progenitor cells (BMDEPCs) in endothelial barrier restoration
following endotoxemic lung injury.

Author Manuscript
Author Manuscript

Approach and Results—We generated mice that enable to quantify proliferating RECs or
BMDEPCs, and also to study the causal link between REC or BMDEPC proliferation and
endothelial barrier restoration. Using these mouse models, we showed that endothelial barrier
restoration was associated with increased REC and BMDEPC proliferation. RECs and BMDEPCs
participate in barrier repair. Immunofluorescence staining demonstrated that RECs proliferate in
situ on endothelial layer, and that BMDEPCs are engrafted into endothelial layer of lung
microvessels at active barrier repair phase. In lungs 8 weeks after LPS-induced injury, number of
REC-derived ECs (CD45−/CD31+/BrdU+/rtTA+) or BMDEPC-derived ECs (CD45−/CD31+/
eNOS+/GFP+) increased by 22- or 121-fold. Suppression of REC or BMDEPC proliferation by
blocking REC or BMDEPC intrinsic NF-κB at barrier repair phase was associated with an
augmented endothelial permeability and impeded endothelial barrier recovery. RECs and
BMDEPCs contributed differently to endothelial barrier repair. In lungs 8 weeks after LPSinduced injury, REC-derived ECs constituted 22%, but BMDEPC-derived ECs constituted only
3.7% of the total new ECs.
Conclusions—REC is a major and BMDEPC is a complementary source of new ECs in
endothelial barrier restoration. RECs and BMDEPCs play important roles in endothelial barrier
restoration following inflammatory lung injury.
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Introduction
Disruption of endothelial barrier and increase in endothelial permeability are major features
of acute lung injury (ALI) associated with sepsis, trauma and hemorrhage.1-3 However, the
mechanisms regulating endothelial barrier restoration are poorly understood. Prior studies
showed that fox head box M1-regulated proliferation genes play important roles.4, 5
However, the “effector” cells that mediated the repair function of fox head box M1 have not
been identified. The origin and function of endothelial cells (ECs) in endothelial barrier
restoration following inflammatory organ injury remain unknown.
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Resident endothelial cell (REC) is long believed to be a major source of ECs in endothelial
repair. Indeed, neighboring RECs were observed to sprout into denuded area after
mechanical arterial endothelial denudation.6 However, the role of RECs in the restoration of
endothelial barrier function after organ injury has not been studied. A causal link between
REC proliferation and endothelial barrier restoration remains to be established. Bone
morrow derived endothelial progenitor cells (BMDEPCs) as a source of ECs in angiogenesis
and endothelial repair has been extensively studied, although whether BMDEPCs contribute
to endothelial or vascular wall is controversial.7-16 Depending on type, nature and severity
of the injury, BMDEPCs were reported to contribute to endothelial and vascular repair in
some experimental models,7-13 but play no role in other models.13-16 Microvascular injury
associated with septic ALI differs significantly from models used in prior reports in nature
and severity. The contribution of BMDEPCs to endothelial barrier repair in septic organ
injury is still unclear. Increased EPC mobilization and/or recruitment were observed in
patients17, 18 and animal models8 with septic organ injury. Autologous transplantation of
EPCs suppressed lung inflammation, attenuated endothelial permeability and lung edema,
and improve outcomes.19, 20 However, it remains unclear whether the exogenous EPCs
improve endothelial barrier function by preventing endothelial injury or by promoting
endothelial repair, or by both. Other investigators have demonstrated that exogenously
administered EPCs or other stem/progenitor cells did not participate in endothelial repair,
but alleviated organ injury and improved outcomes by immunomodulating and paracrine
mechanisms. 21-24 Furthermore, no prior study has examined the causal link between
BMDEPC recruitment/proliferation and endothelial barrier restoration. Thus, whether
BMDEPC is a source of ECs in endothelial barrier restoration remains unclear.

Author Manuscript

To study the causal link between REC or BMDEPC proliferation and endothelial barrier
restoration, we need to examine the functional effect of inhibiting REC or BMDEPC
proliferation on endothelial barrier restoration. Additionally, barrier injury and repair are
interrelated. Severity of injury determines the extent of repair. It is ideal to inhibit REC or
BMDEPC proliferation only at barrier repair phase. Animal model that enables to selectively
inhibit REC or BMDEPC proliferation at barrier repair phase are needed. No such an animal
model has been reported.
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In this study, we took advantage of the fact that endothelial repair depends mainly on
proliferation of EC precursor cells and that the NF-κB pathway is a major pathway
controlling cell proliferation.25-30 We created EC-I-κBα-WT-BM or WT-EC-I-κBα-BM
chimeric mice with doxycycline (Dox)-inducible and REC- or BMDEPC-restricted
overexpression of a mutant I-κBα (I-κBαmt). By treating these mice with Dox after peak of
lung injury, we were able to inhibit REC or BMDEPC proliferation at barrier repair phase
by blocking REC or BMDEPC intrinsic NF-κB activity in a cell-targeted and stage-specific
manner. By performing cause-to-effect studies in combination with cell fate mapping, we
demonstrated that REC is a major and BMDEPC is a complementary source of new ECs in
endothelial barrier repair, and that RECs and BMDEPCs play important roles in endothelial
barrier restoration following inflammatory ALI.

Materials and Methods
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Materials and Methods are available in the online-only Data Supplement.

Results
Active endothelial barrier repair occurs at 48 hours
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Endothelial permeability increased progressively between 0 and 24 hours, associated with
increasing numbers of apoptotic ECs, and decreased progressively between 24 and 96 hours,
associated with decreasing numbers of apoptotic ECs and increasing numbers of
proliferating ECs (Figure 1A, Ref. 30). Based on those observations, we defined 0-24 and
24-96 hours, respectively, as endothelial barrier injury and repair phases. At 48 hours,
endothelial permeability decreased rapidly, associated with the highest level of EC
proliferation (Figure 1A, Ref 30). We considered 48 hour as active barrier repair phase, and
focused our subsequent studies on 48 hours.
Endothelial barrier recovery is associated with increased REC and BMDEPC proliferation
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If RECs and BMDEPCs play important roles in endothelial barrier repair, number of
proliferating RECs or BMDEPCs should increase at active repair phase. To track
proliferating RECs or BMDEPCs in vivo, we generated EC-rtTA-GFP-BM chimeras by
transplanting lethally irradiated EC-rtTA mice31 with bone marrows (BMs) from Tie2-GFP
mice (Supplemental Table I and Table II). These chimeras overexpress the reverse
tetracycline transactivator (rtTA) on RECs and green fluorescent protein (GFP) on
BMDEPCs. Fluorescence activated cell sorting (FACS) analysis of BM mononuclear cells
(BMMNCs) from donors and chimeras 2 months later confirmed that 95% of BM cells in
the chimeras were donor BM origin (Supplemental Figure IA). FACS analysis of peripheral
blood mononuclear cells further confirmed the high degree of BM chimerism in the ECrtTA-GFP-BM mice (data not shown).
The endothelial-specific Tie2 promoter drives GFP expression in endothelial lineage cells.
However, Tie2 was reported to be expressed on a subset of monocytes/macrophages.32 To
clarify the percentage of monocytes in the GFP+ cell population in the lungs, we phenotyped
GFP+ cells from lungs of Tie2-GFP donor mice 48 hours after LPS challenge. We found
that 99% of the GFP+ cells are CD45−/CD31+/eNOS+ endothelial lineage cells, and less
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2016 July 01.
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than 1% of them are CD45+/CD31+ hematopoietic cells (Supplemental Figure II). Our
finding is consistent with a prior report.15 Thus, GFP+ cells in the EC-rtTA-GFP-BM mice
represent principally BMDEPCs.

Author Manuscript

Two months after BM transplantation, mice were injected with saline or LPS, and then with
bromodeoxyuridine (BrdU) to label proliferating cells in vivo. Proliferating RECs or
BMDEPCs, or recruited BMDEPCs were identified by BrdU/rtTA or BrdU/GFP double
staining, or by GFP staining, and counted. Time course analyses showed that endothelial
barrier recovery was associated with remarkably increased REC and BMDEPC proliferation
(Figure 1). In particular, the high numbers of proliferating RECs and BMDEPCs at 48 hours
were concordant with 48 hours being active barrier repair phase. No significant numbers of
proliferating RECs and BMDEPCs were detected at 12 (injury phase) or 96 hours (barrier
function recovered) (Figure 1). ALI was associated with an increased recruitment of GFP+
BMDEPCs in lungs (Figure 1D). However, BMDEPC recruitment was not correlated with
barrier recovery, but correlated with barrier injury (Figures. 1A vs 1D), suggesting that ALI
stimulates BMDEPC recruitment.
RECs participate in endothelial barrier repair

Author Manuscript

If RECs participate in endothelial barrier repair, these cells should proliferate in situ on
endothelial layer at active repair phase to give rise to new ECs. Furthermore, the RECderived daughter ECs should significantly increase in lungs after recovery from injury. ECrtTA-GFP-BM mice that overexpress rtTA only on RECs (Supplemental Table II) were
injected with BrdU at 44 hours after LPS injection to label proliferating cells. Lungs were
harvested at 48 hours or at 8 weeks after LPS injection to track the location of proliferating
RECs or to quantify the REC-derived new ECs in lungs. We visualized endothelial layer by
immunofluorescence staining (IF) of lung sections with rtTA or CD31 antibody. We
identified proliferating RECs by BrdU and rtTA double IF staining. Confocal microscopic
examination revealed that BrdU+/rtTA+ proliferating RECs were localized on the
endothelial layer of microvessels (Figure 2A). The BrdU+/rtTA+ proliferating RECs coexpressed EC marker, CD31, and were localized on the CD31+ endothelial layer, but were
not localized on the aquaporin-5 (Aqu5)+ epithelial layer (Figure 2A). This result provides
histological evidence that RECs proliferate in situ on endothelial layer at active barrier
repair phase

Author Manuscript

FACS analysis showed that number of REC-derived new ECs (CD45−/CD31+/BrdU+/rtTA
+) was approximately 22-fold higher in lungs of EC-rtTA-GFP-BM mice 8 weeks after LPSinduced injury, compared to lungs from mice 8 weeks after saline injection (Figures 2B and
2C). These results provide cytological evidence for REC's participation in endothelial barrier
repair.
BMDEPCs contribute to endothelial barrier repair
BMDEPC incorporation into endothelial layer is a critical step in BMDEPC-mediated
endothelial repair. To seek histological evidence of BMDEPC engraftment, we stained lung
sections from mice 48 hours after LPS injection with antibodies against BMDEPC marker,
GFP, EC markers, CD31 and Ve-cadherin (Ve), or alveolar epithelial cell marker, Aqu5.
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Confocal microscopic examination identified GFP+/CD31+ BMDEPCs localized on the
CD31+ endothelial layer of lung microvessels (Figure 3A). The GFP+ BMDEPCs were also
Ve+, and localized on the Ve+ endothelial layer, but not localized on the Aqu5+ alveolar
epithelial layer (Figure 3A). This result provides evidence for BMDEPC engraftment into
the endothelial layer in the lung at active repair phase.

Author Manuscript

We quantified the engrafted BMDEPCs (CD45−/CD31+/eNOS+/GFP+) in lungs from mice
8 weeks after saline or LPS injection, a time point when organ inflammation and
inflammation-associated BMDEPC recruitment has been subsided. FACS analysis showed
that number of CD45−/CD31+/eNOS+/GFP+ cells was approximately 121-fold higher in
LPS-injected than in saline-injected lungs (Figures 3B and C), indicating an increased
BMDEPC engraftment in injured lungs. These results provide cytological evidence for
BMDEPC engraftment into lung microvessels and suggest that BMDEPC contribute to
endothelial barrier repair.
Different contributions of RECs versus BMDEPCs to endothelial barrier repair
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We next compare the relative contributions of RECs versus BMDEPCs to endothelial barrier
repair. We counted the numbers of proliferating RECs and BMDEPCs in lungs at 48 hours,
and the numbers of REC- and BMDEPC-derived new ECs in lungs 8 weeks after LPSinduced injury. At 48 hours, number of proliferating RECs was 2.4-fold higher than
proliferating BMDEPCs in LPS-challenged lungs, although both proliferating RECs and
BMDEPCs were remarkably higher than control lungs (Figures 4A and 4B). In lungs 8
weeks after LPS-induced injury, total number of new ECs, defined as CD45−/CD31+/BrdU
+ cells, accounted for approximately 2% of total lung cells, which is in agreement with our
previous observation that apoptotic ECs accounted for about 2% of total lung cells in this
mouse model of ALI.30 Among the new EC subpopulation, 83% were rtTA+ (RECderived), but only 9.5% were GFP+ (BMDEPC-derived) (Figures 4C and D).
BMDEPCs may replace apoptotic/dead ECs by differentiation.9 We compared number of
REC-derived ECs (CD45−/CD31+/BrdU+/rtTA+ cells) to number of total engrafted
BMDEPCs (CD45−/CD31+/eNOS+/GFP+ cells), which includes BrdU+ and BrdU-,
BMDEPC-derived ECs, in lungs of EC-rtTA-GFP-BM mice (Supplemental Table II) 8
weeks after LPS injection. REC-derived ECs constituted 22%, but the total engrafted
BMDEPCs constituted only 3.7% of the total CD45−/CD31+ EC population (Figure 4E).
Thus, both histological and FACS analyses revealed that RECs is a major source and
BMDEPCs is a complementary source of new ECs in endothelial barrier repair in the lungs.

Author Manuscript

Targeted inhibition of REC or BMDEPC intrinsic NF-κB activity suppresses REC or
BMDEPC proliferation
We previously demonstrated that Dox-induced I-κBαmt expression inhibited NF-κB in
endothelial lineage cells, but not in other cell types in the EC-I-κBαmt mice.31 Using the
EC-I-κBαmt mice as recipients or donors, we generated EC-I-κBα-WT-BM or WT-EC-IκBα-BM chimeras (Supplemental Table II). We confirmed high level of donor BM
engraftment (>95%) in the chimeras (Supplemental Figures IB and IC). EC-I-κBα-WT-BM
or WT-EC-I-κBα-BM mice overexpress I-κBαmt on RECs or BMDEPCs and enabled us to
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selectively block REC or BMDEPC intrinsic NF-κB activity through Dox-induced I-κBαmt
expression, which leads to the suppression of REC or BMDEPC proliferation.
At 48 hours post-LPS, tissue NF-κB activity is reduced to a low level. Techniques (IF, IHC)
capable of revealing EC-selective NF-κB inhibition are not sensitive enough to detect the
subtle change in NF-κB activity caused by Dox-induced I-κBmt expression. We verified
that treatment of the chimeras with Dox induces I-κBαmt expression and inhibits NF-κB
activity. We showed that injection of EC-I-κBα-WT-BM mice with Dox at 36 hours postLPS induced high level of I-κBαmt mRNA expression (Supplemental Figure III), and
repressed lung tissue level of vascular cell adhesion molecule (VCAM)-1 protein, a widely
used marker of endothelial NF-κB activity, at 48 hours (Figure 5A).

Author Manuscript

Targeted inhibition of REC or BMDEPC intrinsic NF-κB activity suppressed REC or
BMDEPC proliferation. At 48 hours after LPS and 12 hours after Dox injection, number of
proliferating RECs or BMDEPCs in lung sections of EC-I-κBα-WT-BM or WT-EC-I-κBαBM mice (Supplemental Table II, with NF-κB inhibition) were significantly lower than in
lung sections of EC-rtTA-GFP-BM or WT-EC-rtTA-BM mice (Supplemental Table II,
without NF-κB inhibition) (Figures 5B and 5C).
Suppression of REC or BMDEPC proliferation at active repair phase was associated with
an augmented endothelial permeability

Author Manuscript

At 48 hours after LPS and 12 hours after Dox injection, WT mice, in which REC or
BMDEPC proliferation was not inhibited, displayed a moderate increase in endothelial
permeability that is consistent with endothelial barrier repair phase (Figure 5D). EC-I-κBαWT-BM or WT-EC-I-κBα-BM mice, in which REC or BMDEPC proliferation was
inhibited, exhibited a significantly augmented endothelial permeability (Figure 5D).
Blockade of REC intrinsic NF-κB activity caused a 42% reduction in REC proliferation and
41% augmentation of endothelial permeability in the EC-I-κBα-WT-BM mice (Figures 5B
vs 5D), suggesting that augmentation of endothelial permeability and suppression of REC
proliferation are causally related.
Proliferation-independent mechanisms do not contribute to the augmented endothelial
permeability caused by endothelial NF-κB blockade at 48 hours

Author Manuscript

In addition to controlling EC proliferation, NF-κB mediates endothelial permeability by
inducing inflammatory gene expression26 and by disrupting inter-endothelial junctions, as
results of myosin light chain (MLC) phosphorylation, and junction protein internalization
and down-regulation.33-36 To clarify whether these proliferation-independent mechanisms
my contribute to the augmented endothelial permeability caused by endothelial NF-κB
blockade at 48 hours, we compared lung tissue levels of NF-κB-regulated cytokines, TNF-α,
IL-1β, IL-6, and chemokine (C-X-C motif) ligand 1, between mice at 6 and 48 hours to
assess organ inflammatory status at 48 hours, and between WT and EC-I-κBαmt mice to
examine the effects of endothelial NF-κB blockade. We used EC-I-κBαmt mice
(Supplemental Table I), the recipients or donors of EC-I-κBα-WT-BM or WT-EC-I-κBαBM chimeras (Supplemental Table II), for these studies. The use of EC-I-κBαmt mice
enabled us to evaluate the effects of inhibiting REC and BMDEPC intrinsic NF-κB activities
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simultaneously. We also compared tissue levels of phospho-MLC2 and membrane-bound
VE-cadherin, two major markers of disruption of inter-endothelial junctions33-36, between
the two time points and the two groups of mice.

Author Manuscript

Lung tissue levels of the 4 cytokines at 48 hours were higher than controls, but were manyfold lower than at 6 hours, and, importantly, were not affected by EC-restricted NF-κB
inhibition (Supplemental Figures IVA to IVD). At 48 hours post-LPS, lung tissue levels of
phospho-MLC2, and membrane-bound and cytoplasmic VE-cadherin proteins were all at
control levels, and were not affected by EC-restricted NF-κB inhibition (Supplemental
Figures IVE, IVF and V). By contrast, lung tissue level of phospho-MLC2 was several-fold
higher at 3 hours, and level of membrane-bound or cytoplasimic VE-cadherin protein was
several-fold lower or higher at 6 hours than controls and at 48 hours, indicating increased
MLC2 phosphorylation and VE-cadherin internalization at 6 hours, but not at 48 hours. All
these changes were abrogated by EC-restricted NF-κB blockade (Supplemental Figures IVE,
IVF and V). This result excludes the possible involvement of NF-κB-mediated,
proliferation-independent mechanisms in the augmentation of endothelial permeability
caused by endothelial NF-κB blockade at 48 hours.

Discussion

Author Manuscript

This study addresses three fundamental questions that are critical for the understanding of
cellular mechanisms of endothelial barrier restoration following inflammatory organ injury.
First, what are the origins of ECs in endothelial barrier repair and restoration? We
demonstrated for the first time that both RECs and BMDEPCs are important sources of new
ECs in endothelial barrier restoration. Recovery of endothelial barrier function was
associated with a remarkably increased REC proliferation, and increased BMDEPC
proliferation and engraftment. Lungs at active barrier repair phase had the highest level of
REC or BMDEPC proliferation, and increased BMDEPC engraftment. In lungs 8 weeks
after LPS-induced injury, numbers of REC- and BMDEPC-derived ECs increased by 22and 121-fold, respectively. More importantly, suppression of REC or BMDEPC
proliferation at active barrier repair phase (48 hours) was associated with an augmented
endothelial permeability and impeded endothelial barrier recovery.

Author Manuscript

Second, what role does each EC precursor cell play in endothelial barrier restoration? We
showed that although both RECs and BMDEPCs participate in endothelial barrier repair,
their quantitative contributions differ. In lungs at active barrier repair phase, number of
proliferating RECs was more than double of proliferating BMDEPCs. In lungs 8 weeks after
LPS-induced injury, REC-derived ECs constituted 22%, but BMDEPC-derived ECs
constituted only 3.7% of the total CD45−/CD31+ ECs. This result illustrates that REC is a
major and BMDEPC is a complementary source of new ECs in endothelial barrier
restoration following inflammatory ALI.
RECs and BMDEPCs also play different roles in maintaining normal endothelium. In lungs
of mice 8 weeks after saline injection, we detected 1.07% REC-derived new ECs (CD45−/
CD31+/rtTA+/BrdU+), but only 0.03% BMDEPC-derived ECs (CD45−/CD31+/eNOS
+/GFP+) in the EC population (CD45−/CD31+), suggesting that maintenance of normal
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endothelium depends mainly on proliferation of RECs with minimal contribution by
BMDEPCs. This result is in agreement with a prior report showing that maintenance of lung
endothelium does not involve BMDEPCs.15

Author Manuscript

Third, is there a causal link between REC or BMDEPC proliferation and endothelial barrier
restoration? This is the most important question that no previous study has attempted to
address, due to technical challenges. Cell proliferation is regulated by many signaling
pathways and numerous cell cycle regulators with overlapping functions.37, 38 The
redundancy in the regulatory mechanisms makes it extremely difficult to achieve a clear-cut
and high-level inhibition of REC or BMDEPC proliferation by targeting any single
proliferation pathway. Additionally, many of the proliferation-regulating pathways also
regulate other biological processes. This compromises the selectivity in inhibiting cell
proliferation. We may not be able to completely overcome the technical huddles using
currently available animal models, but have to find a way to address this important question.
In this study, we used REC- or BMDEPC-restricted inhibition of NF-κB activity as a means
of suppressing REC or BMDEPC proliferation. We did so for 3 reasons: first, the NF-κB
pathway is a major signaling pathway controlling cell proliferation.25-29 second, animal
models are available in our laboratory31 and third, inhibition of NF-κB-mediated EC
proliferation and inhibition of NF-κB-mediated, proliferation-independent mechanisms have
opposite effects on endothelial permeability, which allow us to reliably assess the effect of
inhibiting REC or BMDEPC proliferation on endothelial barrier restoration. We found that
inhibition of REC or BMDEPC intrinsic NF-κB activity repressed REC or BMDEPC
proliferation by 42% or 44%, implicating the important role of NF-κB pathway in
controlling REC and BMDEPC proliferation, and illustrating the effectiveness of blocking
NF-κB pathway in repressing REC or BMDEPC proliferation.

Author Manuscript
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Suppression of REC or BMDEPC proliferation by REC- or BMDEPC-restricted NF-κB
blockade at 48 hours was associated with an augmented endothelial permeability. We
interpret this augmentation, at least partially, as a consequence of suppressing REC or
BMDEPC proliferation. EC apoptosis is a major mechanism underlying the higher
endothelial permeability at 48 hours post-LPS.30, 39 Replacement of the apoptotic/dead ECs
through proliferation of endothelial precursor cells (RECs and BMDEPCs) is critical to the
restoration of endothelial barrier function. When REC or BMDEPC proliferation is
repressed, particularly at active barrier repair phase, the process of endothelial barrier repair
is impeded and endothelial permeability increased. In supporting this contention, we
demonstrated here that selective blockade of REC or BMDEPC intrinsic NF-κB activity at
48 hours suppressed REC or BMDEPC proliferation and concomitantly augmented
endothelial permeability. Others have demonstrated a causal link between EC apoptosis and
increased endothelial permeability.40-42. Our previous study showed that inhibition of EC
apoptosis ameliorated the augmentation of endothelial permeability caused by endothelial
NF-κB blockade at 48 hours in this ALI model.30,39
In addition to controlling EC proliferation, NF-κB mediates LPS-induced endothelial
permeability by inducing inflammatory gene expression,26 which causes the disruption of
inter-endothelial junctions as results of MLC phosphorylation, EC contraction and junction
protein cytosolic translocation.33-36 However, these mechanisms are unlikely to contribute
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to the augmented endothelial permeability caused by REC- or BMDEPC-targeted NF-κB
inhibition at 48 hours. At this stage, tissue levels of NF-κB-regulated cytokines have
become very low and were not affected by endothelial NF-κB blockade. Tissue levels of
phospho-MLC and membrane-bound VE-cadherin, two major markers of disruption of interendothelial junctions, were at control levels, suggesting that the LPS-induced disruption of
inter-endothelial junctions has been restored at this time point. More importantly, it is well
documented that inhibitions of NF-κB-mediated inflammatory cytokine expression and NFκB-mediated disruption of inter-endothelial junctions decrease, but not increase endothelial
permeability.31, 33-36

Author Manuscript

Other factors may also contribute to the augmentation. NF-κB blockade in BMDEPCs may
inhibit BMDEPC migration, adhesion and incorporation, which can impede BMDEPCmediated barrier repair. However, this mechanism may not contribute to the augmented
endothelial permeability caused by REC-selective NF-κB blockade. Neighboring RECs
replace apoptotic/dead ECs by proliferating in situ on the endothelial layer, and by sprouting
toward the injured site,6 a process that may not involve significant cell migration and
incorporation. To restore endothelial barrier function, the newly generated ECs need to
interact with the existing ECs on the endothelial layer to re-establish normal interendothelial junctions. The effects of NF-κB blockade on these cell-cell interactions warrant
further investigation. Collectively, these results suggest that suppression of REC or
BMDEPC proliferation explains, at least partially, the augmented endothelial permeability
caused by blockade of REC or BMDEPC intrinsic NF-κB activity at 48 hours, implying a
causal relationship between REC or BMDEPC proliferation and endothelial barrier
restoration.
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We demonstrated previously that endothelial NF-κB blockade at 6 hours inhibited LPSinduced endothelial permeability, 31 but showed here that REC- or EPC-targeted NF-κB
inhibition at 48 hours augmented endothelial permeability. This discrepancy could be
explained by different biological function that NF-κB plays at the two time points. At 6
hours, NF-κB mediates the increased endothelial permeability by disrupting interendothelial junctions33-36 without involving significant EC apoptosis.30, 39 Endothelial NFκB blockade at this stage abrogated the disruption of inter-endothelial junctions, but had
little effect on EC apoptosis, resulting in a reduced endothelial permeability. At 48 hours,
the disrupted inter-endothelial junctions have been fully restored and EC apoptosis has
become a predominant mechanism underlying the increased endothelial permeability.
Endothelial NF-κB blockade at this stage inhibited NF-κB-mediated EC proliferation and
promoted EC apoptosis,30,39 both of which impeded barrier recovery and augmented
endothelial permeability. Consistent with this explanation, we showed here that tissue level
of phospho-MLC or membrane-bound VE-cadherin was remarkably high or low at 6 hours,
but was at control level at 48 hours. Endothelial NF-κB blockade abrogated LPS-induced
increase in tissue level of phospho-MLC, decrease in tissue level of membrane-bound VEcadherin and increase in VE-cadherin internalization at 6 hours, but had no effect at 48
hours. Our previous study showed that endothelial NF-κB blockade at 48 hours enhanced
EC apoptosis and concomitantly augmented endothelial permeability.39 Others have
demonstrated a causal link between EC apoptosis and increased endothelial
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permeability.40-42 Although the number of apoptotic/dead ECs is only a small fraction of
total ECs, EC apoptosis/death leads to the formation of pores on endothelium, which
dramatically increase endothelial leakiness.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ALI

acute lung injury

Aqu5

aquaporin-5

BMDEPCs

bone marrow-derived endothelial progenitor cells

BMMNCs

bone marrow mononuclear cells

BrdU

bromodeoxyuridine

DAPI

4',6-diamidino-2-phenylindole

Dox

doxycycline

EC

endothelial cell

eNOS

endothelial nitric oxide synthase

EBD

Evans blue dye

EPCs

endothelial progenitor cells

FACS

fluorescence activated cell sorting

GFP

green fluorescent protein

IF

immunofluorescence

Pro-3

TO-PRO-3 dye

VE-cad

VE-cadherin

MLC2

myosin light chain 2

RECs

resident endothelial cells

rtTA

reverse tetracycline transactivator
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Significance
Disruption of endothelial barrier integrity and increase in endothelial leakiness are
hallmarks of acute lung injury and other inflammatory conditions. However, the origin
and function of new endothelial cells in endothelial barrier repair and restoration are
unknown. Using novel transgenic mouse models, this study identifies resident endothelial
cell (REC) as a major source and bone marrow derived endothelial progenitor cell
(BMDEPC) as a complementary source of new ECs in endothelial barrier repair and
restoration. We provide the first evidence that RECs and BMDEPCs play important
functions in endothelial barrier restoration, and demonstrate a causal relationship
between REC or BMDEPC proliferation and endothelial barrier restoration. Our data
provides important new insights into cellular mechanisms of endothelial barrier repair
and restoration.
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Figure 1. Endothelial barrier recovery is associated with increased resident endothelial cell
(REC) and bone marrow derived endothelial progenitor (BMDEPC) proliferation

Author Manuscript

A: Endothelial permeability in lungs was measured using Evan blue dye (EBD) leakage
index at indicated time (hours) after saline (Con) or LPS (5 mg/kg, i.p.) injection. Means ±
SEM of 6 mice per group. *, p< 0.0.5, compared to control.
B to D: Lung cryosections were prepared at indicated time (hours) after LPS and 4 hours
after 5-bromo-2-deoxyuridine (BrdU) injection, stained with BrdU plus rtTA (reverse
tetracycline transactivator), BrdU plus GFP (green fluorescence protein) or GFP antibodies,
and nuclei counterstained with DAPI (4, 6-diamidino-2-phenylindole). Number of BrdU+/
rtTA+ proliferating RECs (B), BrdU+/GFP+ proliferating BMDEPCs (C) or GFP+ recruited
BMDEPCs (D) was counted and expressed as a percentage of total cells as revealed by
DAPI nuclear staining. Mean ± SEM of 5 mice per group. *, p < 0.05, compared to controls.
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Figure 2. RECs participate in endothelial repair
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A: RECs proliferate in situ on the endothelial layer at active repair phase. Lung sections
from mice 48 hours after LPS injection were stained with antibodies against proliferative
marker, BrdU, REC marker, rtTA, EC marker, CD31, and alveolar epithelial cell marker,
aquaporin-5 (Aqu5), and nuclei counterstained with TO-PRO-3 dye (Pro-3). 3D projections
(A1-A6) or single images (A7-A10) of confocal z-stacks are shown. A1, BrdU+ staining
(green) detects proliferating cells (light blue nuclei). Blue, Pro-3 nuclear staining. A2, rtTA+
staining (red) detects RECs and visualizes the endothelial layer. A3, Merge of A1 and A2
shows BrdU+/rtTA+ RECs (arrow indicated) localized on rtTA+ endothelial layer of
alveolar microvessels. A4 and A5, Orthogonal view (X-Y, X-Z and Y-Z) of the boxed area
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in A3 at higher magnification confirms colocalization of BrdU+ and rtTA+ signals, and
colocalization of BrdU+ and Pro-3+ stainings. Note, the blue nuclear staining in A4 or the
red rtTA staining in A5 was omitted for clarity. A6 and A7, BrdU+/CD31+ RECs (arrow
indicated) are localized on CD31+ endothelial layer of alveolar microvessels. A8-A10,
Higher magnification of the boxed area in A7 is shown. A8, BrdU (green) and CD31 (red)
double stain shows that BrdU+ proliferating REC is localized on CD31+ endothelial layer
(red). A9, BrdU (green) and Aqu5 (blue) double stain shows that BrdU+ proliferating REC
is not localized on Aqu5+ epithelial layer (blue). A10, Merge of A8 and A9 confirms that
BrdU+ REC is localized on the endothelial layer (red) between two epithelial layers (blue).
Scale bars: A1, A2, A3, A6 and A7, 40 μm; A4 and A5, 8 μm; A8, A9 and A10, 3 μm.
B and C: Fluorescence activated cell sorting (FACS) pictures (B) and bar graph (C) show an
increased number of REC-derived ECs, defined as CD45−/CD31+/rtTA+/BrdU+ cells, in
lungs of mice 8 weeks after LPS injection, compared to saline-injected mice (Con). Mean ±
SEM of 5 mice per group. *, p < 0.05, compared with control.
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Figure 3. BMDEPCs contribute to endothelial repair
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A: BMDEPCs engraft into microvessel wall. Lung sections from mice 48 hours after LPS
injection were stained with antibodies against BMDEPC marker, GFP, EC markers, CD31
and Ve-cadherin (Ve), alveolar epithelial cell marker, Aqu5, and nuclei counterstained with
Pro-3 dye. 3D projections (A1 to A6) or single images (A7 to A10) of confocal z-stacks are
shown. A1, GFP+ (green) staining identifies BMDEPCs. A2, CD31+ (red) staining
visualizes the endothelial layer. A3, Merge of A1 and A2 shows engrafted (GFP+/CD31+)
BMDEPCs (yellow cells) localized on CD31+ endothelial layer (red). A4 and A5, 3D (A4)
or orthogonal (A5) projection of the boxed area in A3 at higher magnification confirms
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GFP/CD31 co-expression on the same individual BMDEPC. For clarity, the blue nuclear
staining was omitted. A6 and A7, GFP+/Ve+ BMDEPCs (arrow indicated) are localized on
Ve+ endothelial (red), but not on Aqu5+ epithelial (blue) layer. High magnification of the
boxed area in A7 is shown in A8-A10. A8, GFP (green) and Ve (red) double staining shows
that GFP+ BMDEPCs express Ve (yellow cells), and are localized on Ve+ endothelial layer.
A9, GFP (green) and Aqu5 (red) Double staining shows that GFP+ BMDEPCs do not
express Aqu5 (green cells), and are not localized on Aqu5+ epithelial layer. A10, GFP
(green), Ve (red) and Aqu5 (blue) triple staining confirms that GFP+ BMDEPCs (yellow
cells) are localized on endothelial (red), but not on epithelial (blue) layer. Scale bars: A1,
A2, A3, A6 and A7, 40μm; A4, A5, A8, A9 and A10, 8 μm.
B and C: FACS pictures (B) and bar graph (C) show increased numbers of GFP+/CD31+
cells in the CD45−/CD31+/eNOS+ EC population in lungs of mice 8 weeks after LPS
injection, compared to lungs of mice 8 weeks after saline injection (Con), indicating an
increased BMDEPC engraftment. Mean ± SEM of 5 mice per group. *, p < 0.05, compared
to control mice.
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Figure 4. RECs and BMDEPCs contribute differently to endothelial barrier repair

A: Representative micrographs of rtTA plus BrdU (RECs) or GFP plus BrdU (BMDEPCs)
double staining of lung sections from EC-rtTA-GFP-BM mice 48 hours after saline (Con) or
LPS injection. Number of rtTA+/BrdU+ proliferating RECs was significantly higher than
number of GFP+/BrdU+ proliferating BMDEPCs (arrows indicated). Scale bars, 75 μm.
B: Bar graph shows higher number of proliferating RECs (red bars) than proliferating
BMDEPCs (black bars) in lungs at 48 hours post-LPS. Mean ± SEM of 5 mice per group. *,
p < 0.05, compared to BMDEPCs at 48 hours.
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C and D: FACS pictures (C) and bar graph (D) show that lung cells from EC-rtTA-GFP-BM
mice 8 weeks after LPS injection have a remarkably higher number of REC-derived (rtTA+/
CD31+) than BMDEPC-derived (GFP+/CD31+) ECs in the CD45−/CD31+/BrdU+ new EC
population. Mean ± SEM of 5 mice per group. *, p < 0.05, compared to BMDEPCs.
E: Bar graph shows higher number of REC-derived new ECs (CD45−/CD31+/BrdU+/rtTA
+) than engrafted BMDEPCs (CD45−/CD31+/eNOS+/GFP+) in lung cells from EC-rtTAGFP-BM mice 8 weeks after LPS injection. Mean ± SEM of 5 mice per group. *, p < 0.05,
compared to engrafted BMDEPCs.

Author Manuscript
Author Manuscript
Author Manuscript
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2016 July 01.

Mao et al.

Page 22

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Figure 5. Targeted suppression of REC or BMDEPC proliferation at barrier repair phase
augments endothelial permeability

Wild type (WT), EC-rtTA-GFP-BM (rtTA-GFP), EC-I-κB-WT-BM (I-κB-WT), WT-ECrtTA-BM (WT-rtTA) and WT-EC-I-κBα-BM (WT-I-κB) mice (see Supplemental Table II)
were injected with saline (Con) or LPS (48 Hrs), and then with Dox (0.5 mg/mouse, i.p.) 36
hours after LPS injection. At 48 hours after LPS, lung cryosections were prepared or tissue
level of vascular cell adhesion molecule (VCAM)-1 protein determined, or lung endothelial
permeability measured using EBD index.
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A: Western blot photographs show that Dox-induced I-κBαmt expression at 48 hours
reduces lung tissue level of VCAM-1 protein, an NF-κB-dependent gene product, in EC-IκB-WT-BM mice, indicating an inhibition of REC NF-κB activity. TA-C, EC-rtTA-GFPBM control, I-κB-C, EC-I-κB-WT-BM control, TA48, EC-rtTA-GFP-BM 48 hours, and IκB48, EC-I-κB-WT-BM 48 hours. Representative of 3 independent experiments.
B: and C: Bar graphs show that targeted blockade of REC or BMDEPC intrinsic NF-κB
activity suppresses REC or BMDEPC proliferation. Lung cryosections were stained with
BrdU plus rtTA antibodies and nuclei counterstained with DAPI. Number of BrdU+/rtTA+
proliferating RECs (B) or BrdU+/rtTA+ proliferating BMDEPCs (C) was counted and
expressed as a percentage of total BrdU+ cells. Mean ± SEM of 5 mice per group. *, p <
0.05, compared to Con groups. #, p < 0.05, compared with 48 hour group of rtTA-GFP or
Wt-rtTA mice.
D: Suppression of REC or BMDEPC proliferation by REC- or BMDEPC-targeted NF-κB
blockade was associated with an impeded endothelial barrier recovery. Inhibition of REC
(white vs black bars) or BMDEPC (white vs grey bars) proliferation was associated with an
augmented endothelial permeability. Mean ± SEM of 8 mice per group. *, p < 0.05,
compared with Con groups. #, p < 0.05, compared with WT-48 hour group.
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